High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS G12D Mutated CRC
Thielen, N.; Wei, N.; Nagai, E.; Chu, E.; Kitamura, S.; Kuang, C.
Show abstract
Colorectal cancer (CRC) remains a significant clinical challenge, with a 5-year survival rate of 10%. Over half of all CRCs harbor mutations in the KRAS gene, leading to poor response to standard therapy. This underscores the crucial need for novel therapeutics targeting KRAS and overcoming the growing barrier of resistance. To address these critical challenges, we conducted a high-throughput screen to identify small molecules that synergize with KRAS G12D inhibitor MRTX1133 against CRC. Through screening a 2,652 kinase inhibitor library, we discovered that Osimertinib and its analogs strongly synergize with MRTX1133 against both parental and MRTX1133-resistant cells. The top compound from the screen, NT-1, is a chemical analog of Osimertinib. NT-1 strongly synergized with MRTX1133 to suppress EGFR/MAPK signaling and induce apoptosis in an MRTX1133-resistant patient-derived organoid model of CRC. We present novel small molecule combinations with the potential to overcome the limitations of MRTX1133 with direct clinical translational applications. One Sentence SummaryHigh throughput screening and validation in colon cancer PDOs identifies novel KRAS inhibitor combinations with potential for clinical translation.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Enhancing Intracellular Accumulation and Target Engagement of PROTACs with Reversible Covalent Chemistry 95%
- Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity 95%
- Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19 95%
Similar papers in this journal
- Rapid Resistance To Bet Inhibitors Is Mediated By Fgfr1 In Glioblastoma 96%
- PKIS Deep Dive Yields a Chemical Starting Point for Dark Kinases and a Cell Active BRSK2 Inhibitor 96%
- Epithelial-mesenchymal transition sensitizes breast cancer cells to cell death via the fungus-derived sesterterpenoid ophiobolin A 95%
Similar papers in this journal
- Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer. 94%
- Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors 94%
- Clinical positioning of the IAP antagonist tolinapant (ASTX660) in colorectal cancer 94%
Similar papers in this journal
- A drug's most potent target is not necessarily the source of its anti-cancer activity 96%
- OST Catalytic Subunit Redundancy Enables Therapeutic Targeting of N-Glycosylation 95%
- Structure-aided development of small molecule inhibitors of ENPP1, the extracellular phosphodiesterase of the immunotransmitter cGAMP 94%
Similar papers in this journal
- Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations 96%
- TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers 95%
- Inhibition of both mutant and wild-type RAS-GTP in KRAS G12C colorectal cancer through cotreatment with G12C and EGFR inhibitors 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.